Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US

Author： Rosen Virginia M.

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.28, Iss.1, 2010-01, pp. : 47-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease

By Sun Yan-Ming Wang Lan-Feng Li Jia Li Zhu-Qin Pan Wei

European Journal of Clinical Pharmacology, Vol. 65, Iss. 2, 2009-02 ,pp. : 157-161

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

By Nieminen Tuomo Käähöönen Mika Viiri Leena E Gröönroos Paula Lehtimääki Terho

Pharmacogenomics, Vol. 9, Iss. 10, 2008-10 ,pp. : 1475-1486

Future Medicine

Access to resources Recommend Favorite

Editorial:primary Prevention of Coronary Heart Disease with Lipid Lowering Therapy

By Bernini F. Paoletti R.

Pharmacological Research, Vol. 35, Iss. 3, 1997-03 ,pp. : 167-167

Academic Press

Access to resources Recommend Favorite

Cost Effectiveness of Biventricular Pacemakers in Heart Failure Patients

By Heerey Adrienne

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 2, 2006-01 ,pp. : 129-137

Adis International

Access to resources Recommend Favorite

Nesiritide for the treatment of congestive heart failure

By Iyengar Srinivas Feldman David S Trupp Robin Abraham William T

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 901-907

Informa Healthcare

Access to resources Recommend Favorite